Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist

被引:62
作者
Esposito, Silvano [1 ]
Leone, Sebastiano [1 ]
机构
[1] Univ Naples 2, Dept Infect Dis, Naples, Italy
关键词
ICU infections; antibiotic therapy; appropriate and inappropriate therapy; infectious disease specialist;
D O I
10.1016/j.ijantimicag.2006.10.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Between 5 and 10% of patients admitted to acute care hospitals acquire one or more infections, and the risks have steadily increased during recent decades. Three types of infection account for more than 60% of all nosocomial infections: pneumonia, urinary tract infection and primary bloodstream infection, all of them associated with the use of medical devices. Nearly 70% of infections are due to micro-organisms resistant to one or more antibiotics (multidrug resistant or MDR). A higher incidence of inappropriate antibiotic therapy is expected when infections are caused by antibiotic-resistant micro-organisms and initial inappropriate empirical therapies, and the further need to modify them substantially increases the mortality risk. Despite new antibacterial agents such as linezolid, and also tigecycline and daptomycin, now being available for the treatment of infections due to MDR micro-organisms, the best strategy for improving the cure rate and minimising the development of resistance, probably remains the infectious disease specialist consultation. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:494 / 500
页数:7
相关论文
共 58 条
[21]   Emerging metallo-β-lactamase-mediated resistances:: A summary report from the worldwide SENTRY Antimicrobial Surveillance Program [J].
Fritsche, TR ;
Sader, HS ;
Toleman, MA ;
Walsh, TR ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S276-S278
[22]   Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia [J].
Garbutt, JM ;
Ventrapragada, M ;
Littenberg, B ;
Mundy, LM .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) :466-472
[23]   Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP [J].
Garnacho-Montero, J ;
Ortiz-Leyba, C ;
Jiménez-Jiménez, FJ ;
Barrero-Alodóvar, AE ;
García-Garmendia, JL ;
Bernabeu-Witteli, M ;
Gallego-Lara, SL ;
Madrazo-Osuna, J .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1111-1118
[24]   Vancomycin-resistant Staphylococcus aureus:: no apocalypse now [J].
Goldstein, FW ;
Kitzis, MD .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (08) :761-765
[25]   The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting [J].
Ibrahim, EH ;
Sherman, G ;
Ward, S ;
Fraser, VJ ;
Kollef, MH .
CHEST, 2000, 118 (01) :146-155
[26]   Infection control and changing health-care delivery systems [J].
Jarvis, WR .
EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :170-173
[27]  
JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a
[28]   Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid [J].
Johnson, AP ;
Mushtaq, S ;
Warner, M ;
Livermore, DM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (04) :315-319
[29]   Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy [J].
Kang, CI ;
Kim, SH ;
Park, WB ;
Lee, KD ;
Kim, HB ;
Kim, EC ;
Oh, MD ;
Choe, KW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4574-4581
[30]   Colistin for Klebsiella pneumoniae-associated sepsis [J].
Karabinis, A ;
Paramythiotou, E ;
Mylona-Petropoulou, D ;
Kalogeromitros, A ;
Katsarelis, N ;
Kontopidou, F ;
Poularas, I ;
Malamou-Lada, H .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (01) :E7-E9